Enhertu Gains EU Panel Backing for Expanded HER2+ Solid Tumor Use

A key European Medicines Agency committee issued a positive opinion on 26 May 2026, recommending the approval of Enhertu for adult patients with unresectable or metastatic HER2-positive solid tumors. The CHMP's endorsement, a critical step toward full European Commission authorization, is based on results from the DESTINY-PanTumor02 trial. This tumor-agnostic recommendation marks a significant regulatory milestone for the antibody-drug conjugate developed by Daiichi Sankyo and AstraZeneca. Full marketing authorization for this broad indication is anticipated within two months, potentially expanding the drug's reach beyond its current approvals in breast, gastric, and lung cancers.

Context — why this matters now

The European recommendation follows the US Food and Drug Administration’s accelerated approval of Enhertu for HER2-positive solid tumors in April 2024. That decision was the first FDA approval of a HER2-directed therapy and the first tumor-agnostic approval of an antibody-drug conjugate. The regulatory momentum reflects a strategic pivot in oncology toward biomarker-defined treatments rather than organ-of-origin classifications. This shift accelerates the development pathway for drugs demonstrating efficacy across multiple cancer types with a common molecular driver.

The current macro backdrop for oncology drug development features intense competition and high R&D costs, with companies seeking to maximize the value of successful assets. The global market for HER2-targeted therapies is projected to exceed $20 billion by 2028. The CHMP's positive opinion validates Daiichi Sankyo's and AstraZeneca's strategy of pursuing broad, pan-tumor labels to drive peak sales potential. This approach mitigates the risk associated with the high failure rate of drug development in single-indication trials.

The immediate catalyst was the presentation of updated Phase II data from the DESTINY-PanTumor02 trial at the European Society for Medical Oncology Congress in Q4 2025. The data demonstrated a confirmed objective response rate of 37.1% across multiple tumor types, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and other cancers. This consistent efficacy across diverse cancers with high unmet need provided the clinical evidence required for regulatory review.

Data — what the numbers show

Enhertu generated global sales of approximately $4.2 billion in 2025, a 39% increase over 2024 revenue. The drug is a cornerstone of AstraZeneca’s oncology portfolio, which reported total oncology product sales of $18.4 billion last year. Daiichi Sankyo’s oncology revenue reached ¥1.2 trillion ($7.8 billion) in its 2025 fiscal year, with Enhertu being its largest contributor. A successful pan-tumor approval in the EU could add an estimated $1.5 to $2.0 billion in annual peak sales by 2030, according to consensus analyst estimates.

The DESTINY-PanTumor02 trial reported a median duration of response of 11.3 months for patients receiving Enhertu. The disease control rate, combining complete responses, partial responses, and stable disease, was 68.6%. This performance is particularly notable in cancers like biliary tract, where the objective response rate was 36.4%, significantly higher than the 10-20% range typical for standard chemotherapies. The safety profile was consistent with prior studies, with interstitial lung disease remaining a key monitored risk.

The potential patient population expansion is substantial. While HER2-positive breast and gastric cancers account for the majority of current Enhertu use, other HER2-positive solid tumors represent an estimated 15,000 to 20,000 new eligible patients annually in the EU alone. The prevalence of HER2 positivity varies by cancer type, occurring in approximately 5-10% of biliary tract cancers, 10-15% of bladder cancers, and 15-30% of endometrial cancers.

Analysis — what it means for markets / sectors / tickers

The primary beneficiaries are AstraZeneca (AZN.L, AZN) and Daiichi Sankyo (4568.T). The expanded label protects Enhertu's revenue growth trajectory ahead of key patent expiries for other blockbuster drugs in AstraZeneca's portfolio. For Daiichi Sankyo, it reinforces its position as a leader in antibody-drug conjugate technology. Competitors with HER2-targeted assets, such as Roche (ROG.S) with Herceptin and Perjeta, face increased long-term competitive pressure in niche indications, though their established market share in frontline breast cancer remains formidable for now.

A key risk is the confirmatory Phase III trial, DESTINY-PanTumor03, which is ongoing. The FDA’s accelerated approval and the CHMP’s conditional approval are contingent on verifying clinical benefit in this larger trial. Any failure to confirm the Phase II results could lead to regulatory restrictions or withdrawal of the pan-tumor indication. Pricing and reimbursement negotiations with European national health authorities will also be complex, given the high cost of the drug and the heterogeneity of the new patient population.

Investor positioning has been net long on both AstraZeneca and Daiichi Sankyo since the initial FDA approval, with options flow indicating continued bullish sentiment. Short interest in Daiichi Sankyo remains near a 52-week low of 0.8% of float. The positive CHMP opinion is likely to sustain this trend, though some profit-taking is anticipated following the news. Flow data suggests institutional investors are increasing exposure to the broader oncology segment, particularly companies with platform technologies for targeted therapies.

Outlook — what to watch next

The next immediate catalyst is the European Commission's final decision, expected by late July 2026. A formal approval would trigger launches in major European markets throughout Q4 2026. Investors should monitor reimbursement announcements from Germany’s G-BA and France’s HAS, as these are leading indicators for market access speed and pricing across the EU. Delays or restrictive pricing decisions could temper near-term sales projections.

Key data readouts include updated overall survival data from the DESTINY-PanTumor02 trial, expected at the ESMO Congress in September 2026. Interim results from the confirmatory DESTINY-PanTumor03 trial are projected for H2 2027. Positive overall survival data would strengthen the drug's value proposition and support premium pricing. Enrollment rates for the Phase III trial will be a critical indicator of investigator confidence and patient identification logistics for these rarer tumor types.

For the stocks, technical levels to watch include AstraZeneca’s support at 10,800 pence and resistance at 12,200 pence. Daiichi Sankyo shares are trading near all-time highs; a sustained break above ¥5,200 on high volume would signal continued bullish conviction. The relative performance of the STOXX Europe 600 Health Care Index (SXDP) against the broader STOXX Europe 600 will indicate sector-wide momentum.